PharmaCyte CEO Discusses Firm’s Value Proposition and Milestone Accomplishments Following Recently Published Data on Reversal of Diabetes
PharmaCyte Biotech’s recently appointed CEO, Kenneth L. Waggoner, is solely focused on hitting major milestones and marks 2015 as a banner year for PharmaCyte Biotech, Inc. (OTCQB:PMCB), a Silver Spring, MD-based clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R). The Company recently announced that the world class team of scientists, physicians and academics that make up its international Diabetes Consortium is now complete with the addition of the final two members, Dr. Thomas Stratmann of the University of Barcelona in Spain and Dr. Axel Kornerup Hansen of the University of Copenhagen in Denmark.
The Company also reported that a member of PharmaCyte Biotech’s international Diabetes Consortium, Prof. Ann Simpson, and her colleagues at the University of Technology Sydney and the University of Sydney in Australia published major research describing the “reversal of diabetes in diabetic mice following transplantation of an insulin-secreting human liver cell line: Melligen cells” in the journal Molecular Therapy – Methods & Clinical Development.
In March, the Company announced that the genetically modified cells that are required for its three planned clinical trials in pancreatic cancer patients have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials. BioMedReports spoke to Mr. Waggoner to discuss how he is repositioning PharmaCyte Biotech into one of the sector’s key companies.
The complete interview with CEO, Kenneth L. Waggoner is available now atBioMedReports.com.
Healthcare investors and Biotech traders interested in accessing BioMedReports’ new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to:https://biomedreports.com/fdacal.html.
####
About BioMedReports
BioMedReports is a news and research portal covering financial biotech news for the entireHealthcare Sector of the market. Full disclosures and information about the stocks and information mentioned in this news release are available at BioMedReports.Com
Media Contacts Only:
M. Davila, Assistant Editor
BioMedReports.Com
e-mail: info@biomedreports.com
SOURCE: BioMedReports
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
